PDF(Pubmed)
Abstract：
UNASSIGNED: Involvement of a chemokine known as C-X-C motif chemokine ligand 10 or CXCL10 in the immunopathology of leprosy has emerged as a possible immunological marker for leprosy diagnosis and needed to be investigate further. The purpose of this systematic review is to assess CXCL10\'s potential utility as a leprosy diagnostic tool and evaluation of therapy.
UNASSIGNED: This systematic review is based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020. A thorough search was carried out to find relevant studies only in English and limited in humans published up until September 2023 using PubMed, Scopus, Science Direct, and Wiley Online Library database with keywords based on medical subject headings (MeSH) and no exclusion criteria. The Newcastle-Ottawa Scale (NOS) was utilized for quality assessment, while the Risk of Bias Assessment tool for Non-randomized Studies (RoBANS) was utilized for assessing the risk of bias. Additionally, a narrative synthesis was conducted to provide a comprehensive review of the results.
UNASSIGNED: We collected a total of 115 studies using defined keywords and 82 studies were eliminated after titles and abstracts were screened. We assessed the eligibility of the remaining 26 reports in full text and excluded four studies due to inappropriate study design and two studies with incomplete outcome data. There were twenty included studies in total with total of 2.525 samples. The included studies received NOS quality evaluation scores ranging from 6 to 8. The majority of items in the risk bias assessment, using RoBANS, across all included studies yielded low scores. However, certain items related to the selection of participants and confounding variables showed variations. Most of studies indicate that CXCL10 may be a helpful immunological marker for leprosy diagnosis, particularly in leprosy reactions as stated in seven studies. The results are better when paired with other immunological markers. Its effectiveness in field-friendly diagnostic tools makes it one of the potential biomarkers used in diagnosing leprosy patients. Additionally, CXCL10 may be utilized to assess the efficacy of multidrug therapy (MDT) in leprosy patients as stated in three studies.
UNASSIGNED: The results presented in this systematic review supports the importance of CXCL10 in leprosy diagnosis, particularly in leprosy responses and in tracking the efficacy of MDT therapy. Using CXCL10 in clinical settings might help with leprosy early diagnosis. Yet the findings are heterogenous, thus more investigation is required to determine the roles of CXCL10 in leprosy while taking into account for additional confounding variables.
UNASSIGNED: This systematic review is based on Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020. A thorough search was carried out to find relevant studies only in English and limited in humans published up until September 2023 using PubMed, Scopus, Science Direct, and Wiley Online Library database with keywords based on medical subject headings (MeSH) and no exclusion criteria. The Newcastle-Ottawa Scale (NOS) was utilized for quality assessment, while the Risk of Bias Assessment tool for Non-randomized Studies (RoBANS) was utilized for assessing the risk of bias. Additionally, a narrative synthesis was conducted to provide a comprehensive review of the results.
UNASSIGNED: We collected a total of 115 studies using defined keywords and 82 studies were eliminated after titles and abstracts were screened. We assessed the eligibility of the remaining 26 reports in full text and excluded four studies due to inappropriate study design and two studies with incomplete outcome data. There were twenty included studies in total with total of 2.525 samples. The included studies received NOS quality evaluation scores ranging from 6 to 8. The majority of items in the risk bias assessment, using RoBANS, across all included studies yielded low scores. However, certain items related to the selection of participants and confounding variables showed variations. Most of studies indicate that CXCL10 may be a helpful immunological marker for leprosy diagnosis, particularly in leprosy reactions as stated in seven studies. The results are better when paired with other immunological markers. Its effectiveness in field-friendly diagnostic tools makes it one of the potential biomarkers used in diagnosing leprosy patients. Additionally, CXCL10 may be utilized to assess the efficacy of multidrug therapy (MDT) in leprosy patients as stated in three studies.
UNASSIGNED: The results presented in this systematic review supports the importance of CXCL10 in leprosy diagnosis, particularly in leprosy responses and in tracking the efficacy of MDT therapy. Using CXCL10 in clinical settings might help with leprosy early diagnosis. Yet the findings are heterogenous, thus more investigation is required to determine the roles of CXCL10 in leprosy while taking into account for additional confounding variables.
摘要：
■称为C-X-C基序趋化因子配体10或CXCL10的趋化因子在麻风病的免疫病理学中的参与已成为麻风病诊断的可能的免疫标记，需要进一步研究。本系统评价的目的是评估CXCL10作为麻风病诊断工具和治疗评估的潜在效用。
■本系统评价基于2020年系统评价和荟萃分析（PRISMA）的首选报告项目。进行了彻底的搜索，以找到仅在英语中的相关研究，并使用PubMed在2023年9月之前发表了有限的人类研究。Scopus,科学直接，和Wiley在线图书馆数据库，其关键词基于医学主题词（MeSH），没有排除标准。纽卡斯尔-渥太华量表(NOS)用于质量评估，而非随机研究偏倚风险评估工具(RoBANS)用于评估偏倚风险.此外,进行了叙述性综合，以对结果进行全面审查。
我们总共收集了115项使用定义关键词的研究，82项研究在标题和摘要筛选后被删除。我们在全文中评估了其余26份报告的合格性，并由于研究设计不当而排除了4项研究和2项结果数据不完整的研究。共有20项纳入研究，共2.525个样本。纳入的研究获得了6至8分的NOS质量评估分数。风险偏差评估中的大多数项目，使用Robans,在所有纳入的研究中，得分较低。然而,与参与者选择和混杂变量相关的某些项目显示出差异.大多数研究表明，CXCL10可能是麻风病诊断的一个有用的免疫标记，特别是在七项研究中所述的麻风病反应中。与其他免疫学标记配对时，结果更好。它在现场友好的诊断工具中的有效性使其成为诊断麻风病人的潜在生物标志物之一。此外,如三项研究所述，CXCL10可用于评估麻风病人多药治疗（MDT）的疗效。
■本系统评价的结果支持CXCL10在麻风病诊断中的重要性，特别是在麻风反应和追踪MDT治疗的疗效方面。在临床环境中使用CXCL10可能有助于麻风病的早期诊断。然而这些发现是异质的，因此,需要更多的研究来确定CXCL10在麻风病中的作用,同时考虑其他混杂变量.
■本系统评价基于2020年系统评价和荟萃分析（PRISMA）的首选报告项目。进行了彻底的搜索，以找到仅在英语中的相关研究，并使用PubMed在2023年9月之前发表了有限的人类研究。Scopus,科学直接，和Wiley在线图书馆数据库，其关键词基于医学主题词（MeSH），没有排除标准。纽卡斯尔-渥太华量表(NOS)用于质量评估，而非随机研究偏倚风险评估工具(RoBANS)用于评估偏倚风险.此外,进行了叙述性综合，以对结果进行全面审查。
我们总共收集了115项使用定义关键词的研究，82项研究在标题和摘要筛选后被删除。我们在全文中评估了其余26份报告的合格性，并由于研究设计不当而排除了4项研究和2项结果数据不完整的研究。共有20项纳入研究，共2.525个样本。纳入的研究获得了6至8分的NOS质量评估分数。风险偏差评估中的大多数项目，使用Robans,在所有纳入的研究中，得分较低。然而,与参与者选择和混杂变量相关的某些项目显示出差异.大多数研究表明，CXCL10可能是麻风病诊断的一个有用的免疫标记，特别是在七项研究中所述的麻风病反应中。与其他免疫学标记配对时，结果更好。它在现场友好的诊断工具中的有效性使其成为诊断麻风病人的潜在生物标志物之一。此外,如三项研究所述，CXCL10可用于评估麻风病人多药治疗（MDT）的疗效。
■本系统评价的结果支持CXCL10在麻风病诊断中的重要性，特别是在麻风反应和追踪MDT治疗的疗效方面。在临床环境中使用CXCL10可能有助于麻风病的早期诊断。然而这些发现是异质的，因此,需要更多的研究来确定CXCL10在麻风病中的作用,同时考虑其他混杂变量.
